Health Care · Pharmaceutical Preparations · Nasdaq · CIK 2093101 · FYE Dec 31 · Prices AT CLOSE 2026-07-28 (USD) — end-of-day, never a live or intraday quote
Last $11.49Day −0.69%Mkt cap $197M1Y −66.8%Off 52W high −84.3%Vol (1Y) 103.7%
Daily closing price, split-adjusted to the current basis; 3y shown of 1,943 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest21.0% of sh out |
| Days to cover17.7d |
| 13F net flow (QoQ)−0.01% |
| Top-10 13F concentration49.2% |
| Next report (est.)2026-08-13 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
No standardized fundamentals available.
| YTD−84.1% |
| 1Y−66.8% |
| 3Y+23.5% |
| 5Y−44.7% |
| 10Y−59.7% |
| Since incept. (ann.)−3.9% |
Total return through 2026-07-28 · series begins 2013-06-28. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)103.7% |
| Ann. volatility (3Y)84.7% |
| Sharpe (1Y)−0.12 |
| Sharpe (3Y)0.69 |
| Max drawdown (1Y)−84.2% |
| Max drawdown (3Y)−84.2% |
| Beta (3Y vs SPY)3.10 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| PRICE T ROWE ASSOCIATES INC /MD/ | 1.6M | $21M | 9.08% | new |
| BlackRock, Inc. | 1.2M | $16M | 7.05% | new |
| RA CAPITAL MANAGEMENT, L.P. | 864,102 | $12M | 5.05% | new |
| VANGUARD CAPITAL MANAGEMENT LLC | 626,869 | $8M | 3.66% | new |
| TIG Advisors, LLC | 607,552 | $8M | 3.55% | new |
| Pentwater Capital Management LP | 602,649 | $8M | 3.52% | new |
| O'Connor Alternative Investments LLC | 578,011 | $8M | 3.38% | new |
| Sessa Capital IM, L.P. | 551,391 | $7M | 3.22% | new |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
No reported quarters on file for RNA.
